Oral CBG Cannabis for Cannabis Pharmacology

Behavioral Pharmacology Research Unit, Baltimore, MD
Oral CBG Cannabis +1 morePhase 1RecruitingLed by Cecilia Bergeria, PhDResearch Sponsored by Johns Hopkins University

Study Summary

This trial is designed to study the effects of a cannabis plant constituent, cannabigerol (CBG), on healthy adults. The study will use a placebo-controlled, double-blind design, meaning that neither the participants nor the researchers will know who is receiving the CBG until after the study is completed. The study will consist of 5 conditions, with increasing doses of CBG given orally. Each condition will last for 8 hours, during which time the effects of the CBG will be studied.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Behavioral task performance as assessed by the DRUID app
Blood Pressure
Digit Symbol Substitution Task (DSST) score
+10 more

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Oral administration of 50mg CBGExperimental Treatment1 Intervention
Single acute administration of 50mg CBG suspended in MCT oil.
Group II: Oral administration of 25mg CBGExperimental Treatment1 Intervention
Single acute administration of 25mg CBG suspended in MCT oil.
Group III: Oral administration of 200mg CBGExperimental Treatment1 Intervention
Single acute administration of 200mg CBG suspended in MCT oil.
Group IV: Oral administration of 100mg CBGExperimental Treatment1 Intervention
Single acute administration of 100mg CBG suspended in MCT oil.
Group V: PlaceboPlacebo Group1 Intervention
Single acute administration of oral Placebo liquid (MCT oil).

Find a site


Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,160 Previous Clinical Trials
14,817,693 Total Patients Enrolled
Canopy Growth CorporationIndustry Sponsor
13 Previous Clinical Trials
1,124 Total Patients Enrolled
Cecilia Bergeria, PhDPrincipal Investigator
Johns Hopkins University

Media Library

CHI-914 (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05324982 — Phase 1
Cannabis Pharmacology Research Study Groups: Oral administration of 25mg CBG, Oral administration of 50mg CBG, Oral administration of 100mg CBG, Oral administration of 200mg CBG, Placebo
Cannabis Pharmacology Clinical Trial 2023: CHI-914 Highlights & Side Effects. Trial Name: NCT05324982 — Phase 1
CHI-914 (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05324982 — Phase 1
Cannabis Pharmacology Patient Testimony for trial: Trial Name: NCT05324982 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people currently signing up to participate in this research?

"This study, which is currently seeking participants, was first posted on 8/9/2022 and last edited on 8/16/2022."

Answered by AI

How many people are being recruited for this clinical trial?

"That is correct. The website shows that this trial, which was originally advertised on 8/9/2022, is still looking for participants. They need 30 individuals total from 1 medical facility."

Answered by AI

Are people who are over 25 years old able to participate in this research project?

"Enrolment in this particular study is open to patients that are between 18-55 years old. If the patient does not fall into this age category, there are 49 other trials they could potentially enroll in."

Answered by AI

Is it dangerous to consume Oral CBG Cannabis?

"Oral CBG Cannabis received a score of 1 for safety. This is due to Phase 1 trials having limited data supporting both safety and efficacy."

Answered by AI

Are there any inclusions or exclusions for this research project?

"This clinical trial is enrolling 30 individuals who have previously abused hashish. Patients must be between 18-55 years old and meet the following requirements: They must have given written informed consent, be in good general health based on physical examination, medical history, vital signs, and screening urine/blood tests, test negative for recent cannabis use in urine at Screening Visit and again upon admission for experimental sessions, test negative for other drugs of abuse including alcohol at the Screening Visit and upon arrival for experimental session, not be pregnant or nursing (if female), have a body mass index (BMI) in the range of 18-"

Answered by AI

Who else is applying?

What state do they live in?
What site did they apply to?
Behavioral Pharmacology Research Unit
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

I am dealing with muscle weakness and joint pain and chronic fatigue that varies but seems to be exacerbated by stress; on cpap but still do not get restful sleep. Have taken many different drugs for depression but none have been totally effective. Not inclined to try marijuana as I am already overweight. Quit a 3x /week PT program after 7 weeks because of increase in joint/muscle pain.

What questions have other patients asked about this trial?

How many visits to Baltimore?
~17 spots leftby Jun 2025